LONDON & BURLINGAME, Calif.--(BUSINESS WIRE)--GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and Drug Administration (FDA) has approved a new indication ...

Just 24.7% of elderly patients with chronic obstructive pulmonary disease (COPD) included in the study demonstrated correct usage of their inhaler. Despite all 200 patients included in the study being ...

Sept 9 (Reuters) - GlaxoSmithKline Plc (GSK.L), opens new tab said on Wednesday the U.S health regulator approved its lung disease drug Trelegy Ellipta for expanded use, making it the first inhaler ...

Improvement in lung function was measured using FEV1 (forced expiratory volume in one second). FEV1 is a measurement of how much air you can force out of your lungs in one second. Higher FEV1 values ...

GlaxoSmithKline and Madison, Wisconsin-based Propeller Health announced a partnership today in which Propeller will develop and manufacture a custom sensor for GSK's Ellipta inhaler for COPD patients.

LONDON (Reuters) - Makers of inhalers to treat asthma and chronic lung disease are racing to develop a new generation of smart devices with sensors to monitor if patients are using their puffers ...

GlaxoSmithKline Plc said on Wednesday the U.S health regulator approved its lung disease drug Trelegy Ellipta for expanded use, making it the first inhaler delivering three drugs at once to be ...